Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press25710.17650/1994-4098-2010-0-3-88-94GYNECOLOGY. TREATMENTГИНЕКОЛОГИЯ. ЛЕЧЕНИЕOvarian sarcomas: a review of literatureСаркомы яичников: обзор литературыShvachkoS. A.ШвачкоС. А.
Russian Federation
sashvachko@gmail.comGritsaiA. N.ГрицайА. Н.
Russian Federation
LazarevaN. I.ЛазареваН. И.
Russian Federation
PetersonS. B.ПетерсонС. Б.
Russian Federation
VasilevskayaA. V.ВасилевскаяА. В.
Russian Federation
Department of Oncology, Russian State Medical University, Russian Agency for Health CareКафедра онкологии ГОУ ВПО РГМУ РосздраваN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesГУ РОНЦ им. Н.Н. Блохина РАМНDepartment of Oncology, I.M. Sechenov First Moscow State Medical UniversityКафедра онкологии Первого Московского государственного медицинского университета280820103889428082014280820142010https://ojrs.abvpress.ru/ojrs/article/view/257

The review describes the etiology and clinical features of ovarian sarcomas and current approaches applied to their diagnosis and treatment.

В обзоре освещены этиология, особенности клинического течения и современные подходы, применяемые в диагностике и лечении сарком яичников.

ovarian sarcomacarcinosarcomamixed Mülllerian tumoradenosarcomaendometrial stromal sarcomaundifferentiated sarcomafibrosarcomaсаркома яичниковкарциносаркомасмешанная мюллеровская опухольаденосаркомаэндрометриальная стромальная саркоманедифференцированная саркомафибросаркома1. Le T., Krepart G.V., Lotocki R.J., Heywood M.S. Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20 year experience. Gynecol Oncol 1997;65:237–40.Le T., Krepart G.V., Lotocki R.J., Heywood M.S. Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20 year experience. Gynecol Oncol 1997;65:237–40.2. Rutledge T.L., Gold M.A., McMeekin D.S. et al. Carcinosarcoma of ovary – a case series. Gynecol Oncol 2006;100; 128–32.Rutledge T.L., Gold M.A., McMeekin D.S. et al. Carcinosarcoma of ovary – a case series. Gynecol Oncol 2006;100; 128–32.3. Chang J., Sharpe J.C., A'Hern R.P. et al. Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients. Ann Oncol 1995;6:755–8.Chang J., Sharpe J.C., A'Hern R.P. et al. Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients. Ann Oncol 1995;6:755–8.4. Leiser A.L., Chi D.S., Ishill N.M., Tew W.P. Carcinosarcoma of the ovary treated with platinum and taxane: The memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 2007;105:651–61.Leiser A.L., Chi D.S., Ishill N.M., Tew W.P. Carcinosarcoma of the ovary treated with platinum and taxane: The memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 2007;105:651–61.5. Brown E., Stewart M., Rye I. et al. Carcinosarcoma of the ovary: 19 years of prospective data from single center. Cancer 2004;100:2148–53.Brown E., Stewart M., Rye I. et al. Carcinosarcoma of the ovary: 19 years of prospective data from single center. Cancer 2004;100:2148–53.6. Mano M.S., Rosa D.D., Azambuja E. et al. Current management of ovarian carcinosarcoma. Int J Gynecol Cancer 2007;17:316–24.Mano M.S., Rosa D.D., Azambuja E. et al. Current management of ovarian carcinosarcoma. Int J Gynecol Cancer 2007;17:316–24.7. Berek J.S., Hacker N.F. Practical gynaecologic oncology. 4th ed. Lippincott: Williams and Wilkins, 2005; p. 511–41.Berek J.S., Hacker N.F. Practical gynaecologic oncology. 4th ed. Lippincott: Williams and Wilkins, 2005; p. 511–41.8. Berek J.S., Hacker N.F. Sarcomas of the female genital tract. In: The soft tissue sarcomas. F.R. Eilber et al eds. Orlando: Grune & Stratton, 1987; p. 229–38.Berek J.S., Hacker N.F. Sarcomas of the female genital tract. In: The soft tissue sarcomas. F.R. Eilber et al eds. Orlando: Grune & Stratton, 1987; p. 229–38.9. Sood A.K., Sorosky J.I., Gelder M.S. et al. Primary ovarian sarcoma: Analysis of prognostic variables and the role of surgical cytoreduction. Cancer 1998;82(9):1731–7.Sood A.K., Sorosky J.I., Gelder M.S. et al. Primary ovarian sarcoma: Analysis of prognostic variables and the role of surgical cytoreduction. Cancer 1998;82(9):1731–7.10. Thigpen J., Blessing J.A., DeGeest K. et al. Gynecologic Oncology Group. Cisplatin as initial chemotherapyThigpen J., Blessing J.A., DeGeest K. et al. Gynecologic Oncology Group. Cisplatin as initial chemotherapyin ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol 2004;93:336–9.11. Mok J.E., Kim Y.M., Jung M.H. et al. Malignant mixed Mullerian tumors of the ovary: experience with citoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer 2006;16:101–5.Mok J.E., Kim Y.M., Jung M.H. et al. Malignant mixed Mullerian tumors of the ovary: experience with citoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer 2006;16:101–5.12. Sit A.S., Price F.V., Kelley J.L. et al. Chemotherapy for malignant mixed Mullerian tumors of the ovary. Gynecol Oncol 2000;79:196–200.Sit A.S., Price F.V., Kelley J.L. et al. Chemotherapy for malignant mixed Mullerian tumors of the ovary. Gynecol Oncol 2000;79:196–200.13. Carlson J.A., Edwards C., Wharton J.T. et al. Mixed mesodermal sarcoma of ovary: Treatment with combination radiation therapy and chemotherapy. Cancer 1983;52:1473–7.Carlson J.A., Edwards C., Wharton J.T. et al. Mixed mesodermal sarcoma of ovary: Treatment with combination radiation therapy and chemotherapy. Cancer 1983;52:1473–7.14. Anderson W., Young D.E., Peters W.A. et al. Platinum based combination chemotherapy for malignant mixed mesodermal tumours of the ovary. Gynecol Oncol 1989;32:319–22.Anderson W., Young D.E., Peters W.A. et al. Platinum based combination chemotherapy for malignant mixed mesodermal tumours of the ovary. Gynecol Oncol 1989;32:319–22.15. Plaxe S.C., Dottino P.R., Goodman H.M. et al. Clinical features of advanced ovarian mixed mullein tumours and treatment with doxorubicin and cisplatin chemotherapy. Gynecol Oncol 1990;37:244–9.Plaxe S.C., Dottino P.R., Goodman H.M. et al. Clinical features of advanced ovarian mixed mullein tumours and treatment with doxorubicin and cisplatin chemotherapy. Gynecol Oncol 1990;37:244–9.16. Prendiville J., Murply D., Rennision J. et al. Carcinosarcoma of the ovary treated over a ten year period at the Christie Hospital. Int J Gynecol Cancer 1995;97:219–22.Prendiville J., Murply D., Rennision J. et al. Carcinosarcoma of the ovary treated over a ten year period at the Christie Hospital. Int J Gynecol Cancer 1995;97:219–22.17. Baker T.R., Piver M.S., Caglar H., Piedmonte M. Prospective trial of cisplatin, adriamycin, dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary. Am J Clin Oncol 1991;14: 246–50.Baker T.R., Piver M.S., Caglar H., Piedmonte M. Prospective trial of cisplatin, adriamycin, dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary. Am J Clin Oncol 1991;14: 246–50.18. Crotzer D.R., Wolf J.K., Jenkins A.D. et al. A pilot study of cisplatine, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Proc Am Soc Clin Oncol 2003;24:474.Crotzer D.R., Wolf J.K., Jenkins A.D. et al. A pilot study of cisplatine, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Proc Am Soc Clin Oncol 2003;24:474.19. Zorzou M.P., Markaki S., Rodolakis S. et al. Clinicopathological features of ovarian carcinosarcomas: a single institution experience. Gynecol Oncol 2005;96:136–42.Zorzou M.P., Markaki S., Rodolakis S. et al. Clinicopathological features of ovarian carcinosarcomas: a single institution experience. Gynecol Oncol 2005;96:136–42.20. Sawada M., Tsuda H., Kimura M. et al. Different expression patterns of KIT, EGFR, and HER-2 (c – erbB-Sawada M., Tsuda H., Kimura M. et al. Different expression patterns of KIT, EGFR, and HER-2 (c – erbB-2) oncoprotein between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci 2003;94:986–91.oncoprotein between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci 2003;94:986–91.21. Raspollini M.R., Susini T., Ammuni G. et al. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas a marker for potential molecularly targeted treatment? Int J Gynecol Cancer 2006;16:416–22.Raspollini M.R., Susini T., Ammuni G. et al. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas a marker for potential molecularly targeted treatment? Int J Gynecol Cancer 2006;16:416–22.22. Geisler J.P., Wiemann M.C., Miller G.A. et al. Estrogen and progesterone receptors in malignant mixed mesodermal tumors of the ovary. J Surg Oncol 1995;59:45–7.Geisler J.P., Wiemann M.C., Miller G.A. et al. Estrogen and progesterone receptors in malignant mixed mesodermal tumors of the ovary. J Surg Oncol 1995;59:45–7.23. Czernobilsky B., Gillespie J.J., Roth L.M. Adenosarcoma of the ovary light-and electron-microscopic study with review of the literature. Diagn Gynecol Obstet 1982;4:25–36.Czernobilsky B., Gillespie J.J., Roth L.M. Adenosarcoma of the ovary light-and electron-microscopic study with review of the literature. Diagn Gynecol Obstet 1982;4:25–36.24. Eichhorn J.H., Young R.H., Clement P.B., Scully R.E. Mesodermal (mullerian) adenosarcoma of the ovary:Eichhorn J.H., Young R.H., Clement P.B., Scully R.E. Mesodermal (mullerian) adenosarcoma of the ovary:a clinico-pathologic analysis of 40 cases and a review of the literature. Am J Surg Pathol 2002;26:1243–58.25. Лазарева Н.И. Злокачественные мезенхимальные опухоли женских половых органов (клиника, диагностика, лечение, факторы прогноза). Автореф. дис. ... д-ра мед. наук. М., 2003.Лазарева Н.И. Злокачественные мезенхимальные опухоли женских половых органов (клиника, диагностика, лечение, факторы прогноза). Автореф. дис. ... д-ра мед. наук. М., 2003.26. Anderson B., Turner D.A., Benda J. Ovarian sarcoma. Gynecol Oncol 1987;26:183–92.Anderson B., Turner D.A., Benda J. Ovarian sarcoma. Gynecol Oncol 1987;26:183–92.27. Calvert A.H., Newall D.R., Grumbell L.A. et al. Carboplatin dosage prospective evaluation of a simple formula based on 2 renal function. J Clin Oncol 1989;7: 1748–56.Calvert A.H., Newall D.R., Grumbell L.A. et al. Carboplatin dosage prospective evaluation of a simple formula based on 2 renal function. J Clin Oncol 1989;7: 1748–56.28. Cicin I., Saip P., Eralp Y. et al. Ovarian carcinosarcomas: Clinicopathological prognosis factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol 2008; 108:136–40.Cicin I., Saip P., Eralp Y. et al. Ovarian carcinosarcomas: Clinicopathological prognosis factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol 2008; 108:136–40.29. Dass K.K., Biscotti C.V., Webster K., Saxton J.P. Malignant mixed mullerian tumours of the ovary. An analysis of two long term survivors. Am J Clin Oncol 1993;16(4):346–9.Dass K.K., Biscotti C.V., Webster K., Saxton J.P. Malignant mixed mullerian tumours of the ovary. An analysis of two long term survivors. Am J Clin Oncol 1993;16(4):346–9.30. Garamvoelgyi E., Guillou L., Gebhard S. et al. Primary malignant mixed mullerian tumour (metaplastic carcinoma) of the female peritoneum. Cancer 1994;74(3):854–63.Garamvoelgyi E., Guillou L., Gebhard S. et al. Primary malignant mixed mullerian tumour (metaplastic carcinoma) of the female peritoneum. Cancer 1994;74(3):854–63.31. Hanjani P., Peterson R.O., Lipton S.E., Nolte S.A. Malignant mixed mesodermal tumours of the ovary: Report of eight cases and review of the literature. Obstet Gynecol Surv 1993;38:537–45.Hanjani P., Peterson R.O., Lipton S.E., Nolte S.A. Malignant mixed mesodermal tumours of the ovary: Report of eight cases and review of the literature. Obstet Gynecol Surv 1993;38:537–45.32. Lele S.B., Piver M.S., Barlow J.J. Chemotherapy in the management of mixed mesodermal tumours of the ovary. Gynecol Oncol 1980;10:298–302.Lele S.B., Piver M.S., Barlow J.J. Chemotherapy in the management of mixed mesodermal tumours of the ovary. Gynecol Oncol 1980;10:298–302.33. Marshall R.J. Mixed mullerian tumour of the gynaecological system other than endometrial tumours. In: Textbook of uncommon cancers. Williams C., Krikonan J.G., Green M.R., Raghaven D. eds. Chichester, 1988.Marshall R.J. Mixed mullerian tumour of the gynaecological system other than endometrial tumours. In: Textbook of uncommon cancers. Williams C., Krikonan J.G., Green M.R., Raghaven D. eds. Chichester, 1988.34. Morrow C.P., Ablaing G., Brady L.W. et al. A clinical pathological study of 30 cases of malignant mixed mullerian tumours: A gynaecologic oncology group study. Gynecol Oncol 1984;18:278–92.Morrow C.P., Ablaing G., Brady L.W. et al. A clinical pathological study of 30 cases of malignant mixed mullerian tumours: A gynaecologic oncology group study. Gynecol Oncol 1984;18:278–92.35. Morrow C.P., Bundy B., Hoffman J. et al. Adriamycin chemotherapy for malignant mixed mesodermal tumour of ovary. Am J Clin Oncol 1986;9:24–6.Morrow C.P., Bundy B., Hoffman J. et al. Adriamycin chemotherapy for malignant mixed mesodermal tumour of ovary. Am J Clin Oncol 1986;9:24–6.36. Silasi D.-A., Illuzzi J.L., Kelly M.G., Rutherford T.J. Carcinosarcoma of the ovary. Int J Gynecol Cancer 2008;18:22–9.Silasi D.-A., Illuzzi J.L., Kelly M.G., Rutherford T.J. Carcinosarcoma of the ovary. Int J Gynecol Cancer 2008;18:22–9.37. Silverberg S.G., Kurman R.J. Atlas of tumour pathology, 3rd series Fascicle 3. Washington DC: Armed Forces Institute of Pathology, 1991.Silverberg S.G., Kurman R.J. Atlas of tumour pathology, 3rd series Fascicle 3. Washington DC: Armed Forces Institute of Pathology, 1991.38. Simon S.R., Wang S.E., Uhl M., Shackney S. Complete response of carcinosarcoma of ovary to therapy with doxorubicin, ifosfamide, and dacarbazine. Gynecol Oncol 1991;41:161–6.Simon S.R., Wang S.E., Uhl M., Shackney S. Complete response of carcinosarcoma of ovary to therapy with doxorubicin, ifosfamide, and dacarbazine. Gynecol Oncol 1991;41:161–6.